GSA Capital Partners LLP Invests $675,000 in iRadimed Corporation $IRMD

GSA Capital Partners LLP purchased a new position in shares of iRadimed Corporation (NASDAQ:IRMD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,063 shares of the medical equipment provider’s stock, valued at approximately $675,000. GSA Capital Partners LLP owned approximately 0.06% of iRadimed as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in IRMD. Baader Bank Aktiengesellschaft purchased a new position in iRadimed in the 4th quarter valued at approximately $595,000. Bridge City Capital LLC lifted its holdings in iRadimed by 19.4% during the 4th quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock worth $6,893,000 after buying an additional 11,509 shares during the last quarter. RFG Advisory LLC acquired a new position in iRadimed in the fourth quarter valued at approximately $1,594,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of iRadimed by 144.8% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 15,445 shares of the medical equipment provider’s stock valued at $1,487,000 after buying an additional 9,136 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of iRadimed by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after purchasing an additional 9,017 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 2,500 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer owned 2,162,500 shares in the company, valued at approximately $195,922,500. The trade was a 0.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is owned by corporate insiders.

iRadimed Stock Down 0.2%

Shares of iRadimed stock opened at $87.40 on Thursday. The business’s fifty day moving average is $93.69 and its two-hundred day moving average is $94.62. iRadimed Corporation has a fifty-two week low of $67.84 and a fifty-two week high of $107.90. The firm has a market cap of $1.12 billion, a PE ratio of 48.83 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The firm had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Equities research analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current year.

iRadimed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be issued a $0.20 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 44.69%.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on IRMD shares. Weiss Ratings lowered shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. Wall Street Zen downgraded iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.